================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------------------------
FORM 8-K
-----------------------------------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
FEBRUARY 8, 2000 0-16132
- ----------------------------------------------- -------------------------
Date of Report (Date of earliest event reported) Commission File Number
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 22-2711928
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
7 POWDER HORN DRIVE
WARREN, NEW JERSEY 07059
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(732) 271-1001
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
================================================================================
ITEM 5. OTHER EVENTS.
On February 8, 2000, Celgene Corporation (the "Company")
issued a press release announcing that it had increased the size of its proposed
common stock offering to 3,000,000 shares. Of those shares, 2,484,000 will be
sold by the Company for its own account and the remaining 516,000 shares will be
sold by John Hancock Life Insurance Company and its affiliates. The Company will
also grant to the underwriters an option to purchase an additional 450,000
shares of common stock to cover over-allotments..
The press release is filed as an exhibit hereto and is hereby
incorporated by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) not applicable
(b) not applicable
(c) Exhibits
99.1 Press Release, dated February 8, 2000.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 8, 2000 CELGENE CORPORATION
By: /s/ John W. Jackson
----------------------------
Name: John W. Jackson
Title: Chairman of the Board and
Chief Executive Officer
3
EXHIBIT INDEX
EXHIBIT DESCRIPTION PAGE
- ---------------- ---------------------------------------- --------
99.1 Press Release, dated February 8, 2000.
4